Abstract: The present invention relates to an oral composition having excellent stability and persistence of moderate foaming while sufficiently dispersing biofilm firmly adhered to a tooth surface and showing a good bactericidal effect. That is, the present invention provides an oral composition comprising the following ingredients (A), (B), (C), and (D): (A) 0.001 mass % or more and 0.3 mass % or less of myristoyl glutamic acid or a salt thereof; (B) 0.001 mass % or more and 0.3 mass % or less of lauroyl glutamic acid or a salt thereof; (C) an alkylsulfate; and (D) water, wherein a mass ratio of the content of ingredient (A) to the content of ingredient (B), ((A)/(B)), is 0.25 or more and 4 or less; and the content of a polyphosphoric acid or a salt thereof is 0.01 mass % or less.

Abstract: A flavour composition comprising a compound of formula (I) and edible salts thereof, wherein R1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 double bonds, R1 together with the carbonyl group to which it is attached is a residue of a carboxylic acid.

Abstract: The present invention concerns a process of oxidizing an alcohol for the production of its corresponding carbonyl compounds wherein the oxidation is performed with oxygen or gases containing oxygen in the presence of a catalyst comprising at least a gold compound and a copper compound. Said alcohol oxidation by gaseous oxidant can achieve a high yield and selectivity with minimized degradation products or waste organic solvents.

Abstract: A process of oxidizing an alcohol for the production of its corresponding carbonyl compounds is disclosed, wherein the oxidation is performed with oxygen or gases containing oxygen in the presence of a catalyst comprising at least a gold compound and a copper compound. Said alcohol oxidation by gaseous oxidant can achieve a high yield and selectivity with minimized degradation products or waste organic solvents.

Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

Abstract: A reagent composition for forming fatty acyl amido surfactants is provided which includes an alkali metal or alkaline earth metal salt of an amino compound; a polyol of molecular weight ranging from 76 to 300; and no more than 10% water.

Abstract: A compound has Structure I: where R1 and R2 independently are C2-C12 alkyl groups, R3 and R3? independently are H or CH3, X1 is a C4-C28 alkyl or alkenyl group, and R4 is H or a N,N-bis((meth)acryloylalkyl)-amide group having Structure II: where R5 and R6 independently are C2-C12 alkyl groups, and R3? and R3?? independently are either H or CH3.

Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.

Abstract: Novel chemical conjugates derived from unsaturated fatty acids and therapeutically active agents, are disclosed. The chemical conjugates are designed and characterized as COX-2 and/or 5-LOX inhibitors and are useful in the treatment of inflammatory diseases and disorders such as Alzheimer's disease, Parkinson's disease, asthma, osteoarthritis, rheumatoid arthritis, pain, primary dysmenorrhea, Crohn's disease and ulcerative colitis.

Abstract: A process is provided for preparing C8-C22 acyl glycinate acid or salt thereof via reacting and heating reacting a mixture of glycine or salt thereof with a fatty acid ester in a medium selected from the group consisting of glycerol, propylene glycol and combinations thereof, and wherein the mixture has a pKa ranging from 9.5 to 13.

Abstract: A reagent composition for forming fatty acyl amido surfactants is provided which includes an alkali metal or alkaline earth metal salt of an amino compound; a polyol of molecular weight ranging from 76 to 300; and no more than 10% water.

Abstract: A surfactant concentrate is provided that includes C8-C22 acyl amido compounds, a polyol and C8-C22 fatty acids. The concentrate is formed via an interesterification reaction between a fatty acid ester and an amino compound or salt thereof in a polyol. The resultant surfactant concentrate will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A surfactant concentrate is provided that includes C8-C22 acyl amido compounds, a polyol and C8-C22 fatty acids. The concentrate is formed via an interesterification reaction between a C1-C3 alkyl ester of a C8-C22 fatty acid and an amino compound or salt thereof in a polyol. The resultant surfactant concentrate will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A process is provided for preparing C8-C22 acyl glycinate acid or salt thereof via reacting and heating a mixture of glycine or salt thereof with a C1-C3 alkyl ester of a C8-C22 fatty acid in a medium of glycerol or propylene glycol. The reaction proceeds well where the mixture is formulated to have a pKa ranging from 9.5 to 13.

Abstract: A process is provided for preparing C8-C22 acyl amido compounds via reaction in a polyol (molecular weight 76 to 400) of interesterifying a fatty acid ester with an amino compound or salt thereof. The resultant mass of material will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A method is described for producing acyl glycinate salts of formula (II) in which R1 represents a saturated linear or branched alkyl radical comprising 1 to 21 carbon atoms or a monounsaturated or polyunsaturated linear or branched alkenyl radical comprising 2 to 21 carbon atoms, and B represents a cation, and/or the corresponding protonated acyl glycinic acid. Said method is characterized in that one or more fatty acid monoethanol amides of formula (I) in which R1 has the meaning indicated above is/are oxidized with oxygen in the presence of an optionally supported bimetallic catalyst consisting of gold and a metal from group VIII of the periodic table in the alkaline medium in order to obtain one or more acyl glycinate salts of formula (II). In order to produce the protonated acyl glycinic acids, the acyl glycinate salt/s of formula (II) is/are additionally reacted with an acid.

Abstract: The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with a combination of a monohydroxy functional amine and a specific di-hydroxy functional tertiary alkanolamine, to make an ester tertiary amine, which is a subsequent step is converted to a quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and reacting it with the two type of amine groups allow for the synthesis of a high molecular weight cationic compound which is extremely substantitive to human skin and are well tolerated by human tissue making them suitable for use preparation of barrier products for personal care applications. These materials are dimethylaminopropyl amine free, which is highly desirable in personal care applications.

Abstract: Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADR?1 receptors, and determining based on the binding interaction of the test agent with the ADR?1 receptors whether the test agent is an effective ADR?1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADR?1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.

Abstract: A process is described for preparing acylglycinate salts of the formula (II) in which R1 is a saturated linear or branched alkyl radical having from 1 to 21 carbon atoms or a mono- or polyunsaturated linear or branched alkenyl radical having from 2 to 21 carbon atoms, and B is a cation derived from a base, and/or the corresponding protonated acylglycines, characterized in that one or more fatty acid monoethanolamides of the formula (I) in which R1 is as defined above is oxidized with oxygen in the presence of a transition group metal catalyst in an alkaline medium to give one or more acylglycinate salts of the formula (II), and, in the case of preparation of the protonated acylglycines, the acylglycinate salt(s) of the formula (II) is additionally reacted with an acid.

Abstract: A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid, and wherein the first part, the second part, or both the first and second parts comprise an olefin compound.

Abstract: A method for mixing fluids that can control mixing characteristics of fluids, a method for producing particulates that can provide desired particulates, and particulates produced thereby are provided. According to an embodiment of the present invention, in a method for mixing at least two kinds of fluids in a microreactor, a first fluid is supplied to a mixing zone through a divided supply passage, and a second fluid is supplied to the mixing zone through a supply passage. A total value of dynamic pressures of the first and second fluids is controlled to mix the first and second fluids in the mixing zone. Then, the mixed fluids are flowed into a micro passage.

Abstract: A process is described for preparing acylglycinate salts of the formula (II) in which R1 is a saturated linear or branched alkyl radical having from 1 to 21 carbon atoms or a mono- or polyunsaturated linear or branched alkenyl radical having from 2 to 21 carbon atoms, and B is a cation derived from a base, and/or the corresponding protonated acylglycines, characterized in that one or more fatty acid monoethanolamides of the formula (I) in which R1 is as defined above is oxidized with oxygen in the presence of a transition group metal catalyst in an alkaline medium to give one or more acylglycinate salts of the formula (II), and, in the case of preparation of the protonated acylglycines, the acylglycinate salt(s) of the formula (II) is additionally reacted with an acid.

Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.

Abstract: The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with an alkanolamine to make an ester quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and two amine groups that allow for the synthesis of a high molecular weight cationic compound which is extremely substantitive to human skin and are well tolerated by human tissue making them suitable for use preparation of barrier products for personal care applications. These materials are dimethylaminopropyl amine free, which is highly desirable in personal care applications.

Abstract: The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent of insulin resistance, enhancing agent of insulin sensitivity, therapeutic agent of hypertension, preventive/therapeutic agent of vascular disorders, an anti-inflammatory agent, therapeutic agent of hepatic inflammation, therapeutic agent of fatty liver, therapeutic agent of hepatic fibrosis, therapeutic agent of liver cirrhosis, preventive/therapeutic agent of non-alcoholic/nonviral steatohepatitis (NASH) or non-alcoholic/nonviral fatty liver disease (NAFLD), or therapeutic agent of obesity, each of which has the above compounds as an active ingredient.

Abstract: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds. The present invention further provides methods for the use of such compositions for the treatment of renal or cardiovascular disease and/or related conditions.

Abstract: Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, or the like. Methods for treating medical conditions using the compounds, compositions, or prodrugs described, are also provided.

Abstract: The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease.

Abstract: According to the present invention, a process is provided for producing an acyl group-containing composition that includes a step of reacting a long chain N-acyl acidic amino acid anhydride with one or more compounds which have, per molecule, m functional groups of one kind or more selected from the group consisting of hydroxyl, amino and thiol groups in an aqueous solvent and/or a mixed solvent of water and an organic solvent (reaction step). The process makes it possible to produce an acyl group-containing composition that is free from coloration under moderate conditions.

Abstract: This invention relates to prodrugs of certain amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Abstract: The invention relates to an improved process for oxidizing a primary amidoalcohol to the corresponding amidocarboxylic acid in high yield.

Abstract: The invention relates to an improved process for oxidizing a primary amidoalcohol to the corresponding amidocarboxylic acid in high yield.

Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.

Abstract: The present invention relates to a class of compounds having specific betaines based upon a dimer acid amido amine. Dimer acid is a C-36 diacid having a cyclic structure and two amine groups that allow for the synthesis of a high molecular weight material quaternary compound which is extremely substantitive to human skin and are well tolerated by human tissue making them suitable for use preparation of personal care products.

Abstract: The present invention is a stable, nanometer scale micro-tubular aggregated material of an asymmetric double-headed lipid represented by the general formula R—NHCO—(CH2)n—COOH??(I) (in the formula, R represents an aldopyranose radical from which the terminal reducing hydroxyl group is excluded and n is from six to twenty). The external diameter of the micro-tubular aggregated material is 10-300 nm, and the length is 0.3-10 ?m. The micro-tubular aggregated material can be manufactured by dispersing the asymmetric double-headed lipid described above in water at pH of two to eight, next heating to 80-100° C. to dissolve it and then gradually cooling the aqueous solution obtained.

Abstract: The present invention relates to novel covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids with aminoalcohols of general formula (I) which can usefully be used as agonists of the CB2 cannabinoid receptor and hence as drugs active in pathological conditions which can be controlled by stimulation and/or costimulation of this receptor

Abstract: Novel ceramide compounds, compositions containing them and the use of these compounds, in particular for strengthening the lipid barrier of the epidermis.

Abstract: The present invention ralates to compounds of formula (I): wherein R is hydrogen (H) or C1-6 alkyl; and X is defined such that —NH—(X)—COOH is the residue of an amino acid, which amino acid may itself optionally be substituted at any pendant amino group thereof by a residue of a carboxylic acid or a derivative thereof; or a salt thereof. The use of these compounds, in particular as potential anti-inflammatory and immunomodulatory drugs, and their preparation are described.

Abstract: A desired N-acylamino acid and a salt thereof can be produced efficiently and conveniently, almost without leaving any odor in the object product, by reacting amino acid or a salt thereof with a fatty acid halide under basic conditions in the presence of a phosphorus compound.

Abstract: Provided is a zwitterionic lipid compound represented by formula (I) given below: 1

Abstract: Amino acid derivative as carrier compounds and compositions which are useful in the delivery of active agents are provided. The active agents can be a peptide, mucopolysaccharide, carbohydrate, or lipid. Methods of administration, including oral administration, and preparation are provided as well.

Abstract: Novel ceramide compounds, compositions containing them and the use of these compounds, in particular for strengthening the lipid barrier of the epidermis.

Abstract: Amino acid derivative as carrier compounds and compositions which are useful in the delivery of active agents are provided. The active agents can be a peptide, mucopolysaccharide, carbohydrate, or lipid. Methods of administration, including oral administration, and preparation are provided as well.

Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.

Abstract: A fuel additive composition composed of the reaction product of (a) mixed fatty acid esters; (b) a mono or di-(hydroxy alkyl amine) or mixtures thereof; and (c) a low temperature property enhancing effective amount of a low molecular weight ester; wherein the reaction mixture has a molar ratio of amine to total ester content in the range from 10.0 to 1.0. The fuel additive exhibits detergent and friction reducing properties when added to a fuel thereto and further exhibits good low temperature stability properties. Methods for making the inventive composition and fuel compositions containing the additive are also disclosed.

Abstract: A composition useful as a well lubricant, solvent, emulsifier, and performance extender for corrosion inhibitors in high velocity gas, oil or water drilling, production or gathering applications, that is preferably formed by the reaction and distillation of a tall oil fatty acid with a fatty alkanolamide, preferably in the presence of methyl ester of fatty acids, and most preferably when further reacted and distilled with an emulsifier such as coconut oil diethanolamide or distilled tall oil amide of aminoethylpiperazine. The fatty acids and oils useful in the invention can range from C8 to C24, with C12, C14, C16, C18 and C20 fatty acids and oils being most preferred. The presence of methyl ester is preferred because it functions as a foam suppressant, diluent and amine scavenger during distillation.

Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.

Abstract: The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide (hereinafter referred to as a “protected/activated salicylamide”). The method comprises the steps of (a) alkylating the protected/activated salicylamide with an alkylating agent to form a protected/activated alkylated salicylamide, and (b) deprotecting and deactivating the protected/activated alkylated salicylamide, simultaneously or in any order, to form the alkylated salicylamide. The alkylated salicylamides prepared by this method are suitable for use in compositions for delivering active agents via oral or other routes of administration to animals.

Abstract: An acylamino acid for enhancing the bio-availability of substances in organisms by permeabilization of cell membranes, the acylamino acid having general formula (I) wherein R1 is hydrogen, a primary, secondary or tertiary alkyl or alkenyl group and R2 is hydrogen, a straight or branched chain alkyl group or a straight or branched chain substituted alkyl group, the substituted being selected from thio, thioether, hydroxy, carboxy, quarternary ammonium, amide, heterocyclic, benzyl, substituted benzyl, amino, substituted amino groups and difunctional alkyl groups linking to the nitrogen atom. A preferred acylamino acid for incorporating into an animal or fish feed is 2-palmitoylaminoproprionic acid.

Abstract: A fatty acid amphoteric surfactant complex obtained by mixing a) at least one imidazolinium ampholytic surfactant of the formula: wherein R1 represents an alkyl or alkenyl group having 9 to 17 carbon atoms on average; and Z is 1 or 2; with b) a higher fatty acid selected from the group consisting of oleic acid, isostearic acid and a mixture of oleic acid and isostearic acid; wherein the ratio of said higher fatty acid to the total amount of said imidazolinium ampholytic surfactant(s) in said complex ranges from about 25:75 to 90:10. The complex containing an ampholytic and/or semipolar surfactant and higher fatty acid may optionally contain a clay mineral. Said complex may be employed in making emulsions.